Evidence map›Paper›PMID 40861202›Full record

ArticleFrontiers in medicine2025

Analysis of the efficacy of avatrombopag for the delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation for aplastic anemia.

Xinhe Zhang, Jia Feng, Zhengwei Tan, Herui Zhang, Huijin Hu, Yuechao Zhao, Dijiong Wu, Yu Zhang, Liqiang Wu, Tonglin Hu and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Xinhe ZhangNanyang First People's Hospital, Nanyang, China.
Jia FengThe First Clinical College of Zhejiang Chinese Medical University, Hangzhou, China.
Zhengwei TanThe First Clinical College of Zhejiang Chinese Medical University, Hangzhou, China.
Herui ZhangThe First Clinical College of Zhejiang Chinese Medical University, Hangzhou, China.
Huijin HuThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Yuechao ZhaoThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Dijiong WuThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Yu ZhangThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Liqiang WuThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Tonglin HuThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Zhengsong YanThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Baodong YeThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Wenbin LiuThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Delayed platelet engraftment (DPE) after allo-HSCT lacks standard therapy. Avatrombopag (AVA), a second-generation TPO agonist, is often delayed until transfusion-related events occur, potentially harming high-risk recipients. Objectives: We compared recombinant human thrombopoietin (rh-TPO) with early AVA switching for treating DPE in aplastic anemia (AA) patients post-allo-HSCT to optimize management strategies. Methods: This single-center study retrospectively enrolled 154 consecutive AA patients receiving allo-HSCT at Zhejiang Provincial Hospital of Traditional Chinese Medicine (March 2019-September 2023). Of these, 39 deemed high-risk for poor platelet engraftment (advanced donor/recipient age, low CD34 + dose, etc.) were non-randomly assigned: (1) AVA group ( Results: Our findings revealed that the 1-year overall survival (OS) rate was notably higher in AVA group (100% vs. 78.6%, Conclusion: For patients identified as being at high risk for poor platelet engraftment following allo-HSCT, early transition to AVA can significantly reduce the duration of DPE and promote platelet recovery post-transplantation. This strategy has the potential to enhance patient survival rates and overall outcomes.

Indexed as

Allo-HSCTavatrombopagDPERhTPOTPO-RA

Identifiers

PMID40861202
PMCPMC12370753

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.